Predictive Oncology Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Predictive Oncology.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.2%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why We're Watching Predictive Oncology's (NASDAQ:POAI) Cash Burn Situation

Jun 29

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Predictive Oncology no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:POAI - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	2	-14	-13	-13	N/A
9/30/2023	2	-18	-14	-13	N/A
6/30/2023	2	-19	-13	-13	N/A
3/31/2023	1	-26	-13	-13	N/A
12/31/2022	2	-26	-13	-12	N/A
9/30/2022	2	-26	-13	-13	N/A
6/30/2022	1	-27	-14	-13	N/A
3/31/2022	1	-19	-13	-12	N/A
12/31/2021	1	-20	-13	-12	N/A
9/30/2021	1	-23	-12	-11	N/A
6/30/2021	1	-25	-12	-11	N/A
3/31/2021	1	-26	-13	-13	N/A
12/31/2020	1	-26	-13	-12	N/A
9/30/2020	1	-29	-13	-13	N/A
6/30/2020	1	-26	-11	-11	N/A
3/31/2020	1	-21	-10	-10	N/A
12/31/2019	1	-20	-9	-9	N/A
9/30/2019	1	-9	-7	-7	N/A
6/30/2019	1	-8	-6	-6	N/A
3/31/2019	1	-12	-6	-6	N/A
12/31/2018	1	-10	-6	-5	N/A
9/30/2018	1	-8	-6	-5	N/A
6/30/2018	1	-6	-6	-5	N/A
3/31/2018	1	-6	-5	-5	N/A
12/31/2017	1	-6	-5	-4	N/A
9/30/2017	1	-6	N/A	-4	N/A
6/30/2017	1	-6	N/A	-4	N/A
3/31/2017	1	-6	N/A	-4	N/A
12/31/2016	0	-7	N/A	-4	N/A
9/30/2016	1	-8	N/A	-7	N/A
6/30/2016	0	-8	N/A	-10	N/A
3/31/2016	1	-7	N/A	-9	N/A
12/31/2015	1	-5	N/A	-7	N/A
9/30/2015	1	-5	N/A	-5	N/A
6/30/2015	1	-5	N/A	-2	N/A
3/31/2015	1	-5	N/A	-2	N/A
12/31/2014	1	-7	N/A	-3	N/A
9/30/2014	1	-7	N/A	-4	N/A
6/30/2014	1	-9	N/A	-4	N/A
3/31/2014	0	-9	N/A	-5	N/A
12/31/2013	0	-9	N/A	-4	N/A
9/30/2013	0	-9	N/A	-4	N/A
6/30/2013	0	-8	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de POAI es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de POAI crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de POAI crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de POAI crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de POAI crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de POAI se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Predictive Oncology Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased to US$5.00

Price target increased to US$4.50

Predictive Oncology Inc. Provides Earnings Guidance for the Year 2021, 2022 and 2023

Recent updates

New minor risk - Share price stability

New major risk - Market cap size

Full year 2023 earnings released: US$3.48 loss per share (vs US$7.05 loss in FY 2022)

Predictive Oncology Inc. Announces Resignation of Pamela Bush, as Chief Business Officer, Effective from February 15, 2024

Predictive Oncology Inc., Annual General Meeting, Dec 28, 2023

Third quarter 2023 earnings released: US$0.79 loss per share (vs US$1.04 loss in 3Q 2022)

Predictive Oncology Inc. to Report Q3, 2023 Results on Nov 14, 2023

Predictive Oncology Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$3.02 loss in 2Q 2022)

Predictive Oncology Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023

Predictive Oncology Inc. to Report Q2, 2023 Results on Aug 10, 2023

Here's Why We're Watching Predictive Oncology's (NASDAQ:POAI) Cash Burn Situation

Predictive Oncology Inc. Appoints Andrew Einhorn to Its Business Advisory Board

Predictive Oncology Inc. Appoints Dr. Bernard A. Harris, Jr. to Its Newly Formed Business Advisory Board

First quarter 2023 earnings released: US$0.86 loss per share (vs US$1.02 loss in 1Q 2022)

Predictive Oncology Inc. to Report Q1, 2023 Results on May 15, 2023

High number of new and inexperienced directors

Full year 2022 earnings released: US$0.35 loss per share (vs US$0.36 loss in FY 2021)

Predictive Oncology Inc. Appoints Pamela Bush as Chief Business Officer

Predictive Oncology Inc. Appoints Robert F. Murphy, Ph.D. to the Scientific Advisory Board

Predictive Oncology Inc. Announces Appointment of Marc Malandro, Ph.D., to the Company's Scientific Advisory Board

Predictive Oncology Appoints Matthew J. Hawryluk Ph.D. to the Board of Directors

Price target increased to US$5.00

Third quarter 2022 earnings released: US$0.052 loss per share (vs US$0.083 loss in 3Q 2021)

Predictive Oncology Eligible for an Additional 180-Day Calendar Period, or Until May 8, 2023, to Regain Compliance

Predictive Oncology Appoints David S. Smith to the Company's Board of Directors

Predictive Oncology Appoints Raymond F. Vennare as Chief Executive Officer Effective November 1, 2022

Predictive Oncology has a new CEO

Predictive Oncology Inc., Annual General Meeting, Dec 01, 2022

Predictive Oncology Inc. Announces Retirement of J. Melville (“Mel”) Engle as Chairman and A Member of Board of Directors

Predictive Oncology announces retirement of CEO Mel Engle

Second quarter 2022 earnings released: US$0.075 loss per share (vs US$0.05 loss in 2Q 2021)

Predictive Oncology Inc. Announces Unaudited Consolidated Impairment Charges for the Three Months Ended June 30, 2022

Predictive Oncology Appoints Julia Kirshner as Chief Scientific Officer, Effective August 1, 2022

Predictive Oncology Inc. Announces Christina Jenkins Intends to Resign as Director, Effective August 31, 2022

Insider recently bought US$62k worth of stock

Predictive Oncology Receives Non-Compliance Letter from Nasdaq

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$4.50

Predictive Oncology Inc. Appoints Theresa Ferguson as Senior Director of Marketing

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Predictive Oncology Regains Compliance with Nasdaq Listing Rule 5550(a)(2), Requiring a Minimum Bid Price

Predictive Oncology Inc. Reports Strong Results from Its AA Cancer Drug Evaluation

High number of new directors

Predictive Oncology Inc. (NasdaqCM:POAI) acquired zPREDICTA, Inc. for $10 million.

Third quarter 2021 earnings released: US$0.083 loss per share (vs US$0.46 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.05 loss per share (vs US$0.36 loss in 2Q 2020)

Predictive Oncology Inc. Provides Earnings Guidance for the Year 2021, 2022 and 2023

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.93 loss in 1Q 2020)

Director has left the company

CEO & Director Carl Schwartz has left the company

Full year 2020 earnings released: US$2.21 loss per share (vs US$6.86 loss in FY 2019)

Predictive Oncology’S, Skyline Medical Division, Developing Generation 3 Direct-To-Drain Automated Fluid Waste Management System

Predictive Oncology Inc. Completes Key Data Generation Milestones in Its Retrospective Study

Predictive Oncology Inc. announced that it expects to receive $17.635344 million in funding

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $7.389004 million.

Predictive Oncology Announces the Start of Its Drug Repurposing Project Using Its Ground-Breaking Pedal™ Platform for Ovarian Cancer

New 90-day high: US$1.40

Predictive Oncology Regains Compliance with Nasdaq Minimum Bid Price Requirement

Predictive Oncology regains Nasdaq compliance

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $4.097964 million.

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $2.2 million.

Predictive Oncology Inc. has completed a Follow-on Equity Offering in the amount of $3.074007 million.

New 90-day high: US$0.90

Third quarter 2020 earnings released: US$0.46 loss per share

New 90-day low: US$0.72

Predictive Oncology Receives A Letter from the Listing Qualifications Department Nasdaq Stock Market

Predictive Oncology Inc. announced that it has received $1.370002 million in funding

Precision Therapeutics Inc. Announces Executive Appointments

New 90-day low: US$0.83

Predictive Oncology Inc. (NasdaqCM:POAI) completed the acquisition of Assets of Quantitative Medicine, LLC for $2.6 million.

Predictive Oncology Inc. (NasdaqCM:POAI) entered into a letter of intent to acquire Assets of Quantitative Medicine, LLC.